New drugs for methicillin-resistant Staphylococcus aureus: an update.
Methicillin-resistant Staphylococcus aureus (MRSA) remains a leading cause of bacterial infections worldwide, with a dwindling repertoire of effective antimicrobials active against it. This review aims to provide an update on novel anti-MRSA molecules currently under pre-clinical and clinical development, with emphasis on their mechanism of action. This review is limited to molecules that target the pathogen directly and does not detail immunomodulatory anti-infectives.